Patients and methods: Forty-eight patients received the combination of raltitrexed plus oxaliplatin.
2
These data indicate that survivin may be a key target for oxaliplatin.
3
This study investigated the addition of oxaliplatin with and without preoperative radiotherapy.
4
The platinum-based chemotherapeutic agent oxaliplatin displays a wide range of antitumor activities.
5
Further investigations indicated that survivin promoter activity was also inhibited by oxaliplatin.
1
Sanofi's outlook excludes a return of generics to its cancer drug Eloxatin in the United States.
2
Sanofi said net sales of Eloxatin fell 2.9 percent and net sales of Ambien fell 64.6 percent in the fourth quarter.
3
Sanofi said that without the impact of copies of Ambien in the U.S. and Eloxatin in Europe, second-quarter sales would have been up 7.1 percent.
1
Furthermore, L-OHP and fluorouracil combination was shown to be synergistic both in experimental studies and in clinical trials.
2
Pre-clinical studies from human cell lines suggested that L-OHP was efficacious in treating advanced or recurrent colorectal cancer.
3
Thus, introduction of irinotecan and L-OHP into clinical use has been a major advances for patients with metastatic colorectal cancer.
4
Conclusion: Palliative second-line treatment according to the AIO regimen plus L-OHP is feasible in an outpatient setting and well tolerated by the patients.